Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- Registration Number
- NCT04851613
- Lead Sponsor
- Laekna Limited
- Brief Summary
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
- Detailed Description
Eligible patients for this study must have either (1) progressive disease whilst receiving an endocrine therapy (AI or a SERM), and/or a CDK4/6 inhibitor for locally advanced or metastatic disease; or (2) relapsed with metastatic disease whilst receiving an ET (AI or SERM), and/or a CDK4/6 inhibitor, and/or chemotherapy in adjuvant setting. No more than 2 prior lines of systemic treatments for locally advanced or metastatic disease are allowed for this study, including 1-2 prior lines of endocrine therapy, with/without CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 therapy).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 256
-
Female or male patients must be ≥ 18 years of age on the day of signing the informed consent and be able to provide written informed consent for the study.
-
Patients with histologically or cytologically confirmed HR+/HER2- BC characterized by the absence of HER2 expression and the presence of ER and/or PR expression.
-
HR+/HER2- BC patients must meet all the following criteria to join this study:
- Relapsed locally advanced (LABC) or metastatic (mBC) disease; AND
- Have received 1 to 2 prior lines of systemic treatments for LABC or mBC(at least one line was ET).
-
For phase Ib part, patients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1 criteria; for phase III, have measurable disease and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.
-
In the Phase Ib part, Patients must provide informed consent for the procedures and the tests for PIK3CA/AKT/PTEN alterations and ESR1 mutations. The biomarkers will be tested retrospectively by gene sequencing tests using archival tumor sample (preferably within 18 months/78 weeks) or from peripheral blood or from a tumor biopsy sample. Formalin-fixed, paraffin embedded (FFPE) tissue blocksare preferred. In phase III, blood sample is mandatory for this test.
-
In Phase III, subjects need to provide blood sample during the screening period for PIK3CA/AKT1/PTEN test, which will be conducted in the central laboratory. Only patients with PIK3CA/AKT1/PTEN alterations could include.
-
Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
-
Patients who have adequate organ function
-
Female patients of childbearing potential must have a negative pretreatment serum pregnancy test.
-
Female patients of childbearing potential must agree to use effective contraception from enrollment to 1 year after discontinuation from the last dose of this study treatment,
-
Patients who are able to swallow and retain oral medication and without gastrointestinal diseases to interfere with drug absorption.
-
Patients must have no contraindications to fulvestrant.
- Patients who had a recent major surgery that required hospitalization for longer than 48 hours (< 8 weeks from scheduled treatment starting date) or have used IV antibiotics for the treatment of systemic infection (< 2 weeks from scheduled treatment starting date).
- Patients who have additional known malignancies that are progressing or have required active treatments within 3 years of scheduled treatment starting date. (Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, that have undergone potentially curative therapy are not excluded).
- Patients who have a history of seizure or conditions that may predispose them to seizure and require anti-epileptic medications, or patients who have brain arteriovenous malformation, or intracranial masses that are causing edema or clinical symptoms.
- Patients who have known active CNS metastases and/or carcinomatous meningitis.
- Patients who had prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), or any PI3K/AKT/mTOR inhibitors, or any CDK4/6 inhibitors in phase I, II study.
- Patients with QT interval corrected by the Frederica's correction formula (QTcF) > 470 msec
- Patients who have uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg under anti-hypertensive treatment).
- Patients with active Hepatitis B infection [defined as HBsAg (+) and HBV-DNA ≥ 200 IU/ml (1000 copy/ml)] or active Hepatitis C virus [defined as HCV antibody positive and HCV RNA (qualitative) test positive].
- Patients with known HIV seropositivity
- Patients who are receiving medications that are sensitive substrates of CYP3A4, OATP1B1, or BCRP with low therapeutic index.
- Patients who are ineligible for endocrine therapy (e.g., visceral crisis, inflammatory breast cancer).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Phase I: Afuresertib and Fulvestrant Safety Run In Afuresertib Phase I: Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles. Phase III:placebo combined with fulvestrant (control arm) Afuresertib/placebo PhaseIII：placebo combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1) Phase I: Afuresertib and Fulvestrant Afuresertib Phase I: Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles. Phase III: afuresertib combined with fulvestrant (experimental arm) Afuresertib/placebo Phase III: afuresertib 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
- Primary Outcome Measures
Name Time Method Phase I: Overall Response Rate (ORR) based on RECIST 1.1 Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase III:To assess the anti-tumor activity of the combination therapy with afuresertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations HR+/HER2- BC who have failed 1 to 2 prior lines of ET with/without a Phase III: CDK4/6 inhibitor (up to 1 therapy), or chemotherapy (up to 1 chemotherapy)
- Secondary Outcome Measures
Name Time Method Phase I: Duration of Response (DOR) based on RECIST 1.1 Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase I: Disease Control Rate (DCR) based on RECIST 1.1 Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase I: Best Overall Response (BOR) based on RECIST 1.1 Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase I: Progression Free Survival (PFS) based on RECIST 1.1 Phase I: After Cycle 3 Day 1 and then every 8 weeks x 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase I: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase I: Pharmacokinetics- Time to Maximum Concentration (T-Max) Phase I: Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days) Phase I: Time to peak level of afuresertib
Phase I: Pharmacokinetics- Area Under the Curve (AUC) Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days) Area under the curve of afuresertib
Phase I: Frequency and severity of Adverse Events (AEs) Phase I: Through study completion for an average of 12 months Phase I: findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0
Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by BICR Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days) Phase III: Anti-tumor activity of the combination therapy with afuresertib plus fulvestrant in patients with HR+/HER2- BC
Phase III：Frequency and severity of Adverse Events (AEs) Phase III：Through study completion Phase III：findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0
Phase III：Pharmacokinetics- Time to Maximum Concentration (T-Max) Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days) Time to peak level of afuresertib
Phase III：Pharmacokinetics- Area Under the Curve (AUC) Assessed on Day 1 and Day 15 of Cycle 1 (each cycle is 28 days) Area under the curve of afuresertib
Trial Locations
- Locations (7)
Providence St. Johns Health Center
🇺🇸Santa Monica, California, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Piedmont Cancer Institute
🇺🇸Atlanta, Georgia, United States
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China
University of Iowa
🇺🇸Iowa City, Iowa, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
University of Vermont
🇺🇸Burlington, Vermont, United States